Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 73 clinical trials
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

This is a randomized, open-label, multi-center, phase III study of Napabucasin plus bi-weekly FOLFIRI (Arm 1) vs. Napabucasin (Arm 2) for adult patients with metastatic CRC who have failed

  • 27 views
  • 23 Jan, 2021
  • 37 locations
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer

Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways. Giving combination chemotherapy together with CMAB009 as first treatment after diagnosis of …

metastasis
folfiri regimen
leucovorin
irinotecan
measurable disease
  • 3 views
  • 25 Jan, 2021
  • 2 locations
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI

metastasis
adjuvant chemotherapy
cetuximab
fluorouracil
folfox regimen
  • 6 views
  • 21 Jan, 2021
  • 1 location
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth …

tumor cells
leucovorin
adjuvant therapy
calcium
monoclonal antibodies
  • 7 views
  • 07 Nov, 2020
  • 1 location
Investigation of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance to FOLFIRI treatment. The study is divided in

ct scan
metastasis
KRAS
folfiri regimen
oxaliplatin
  • 0 views
  • 25 Jan, 2021
  • 1 location
FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma

This phase study was designed to evaluate the efficacy and safety of FOLFIRI as second-line treatment for metastatic esophageal carcinoma.

  • 7 views
  • 23 Jan, 2021
  • 1 location
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

FOLFIRI or CAPTEM as second line treatment. Disease control rate (DCR) and safety are primary objectives, secondary objectives are Disease control rate (OS), Progression Free Survival (PFS), quality of

metastasis
tubal ligation
etoposide
ki-67
everolimus
  • 28 views
  • 03 Mar, 2021
  • 23 locations
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two parallel arms will be conducted to compare irinotecan dose escalated FOLFIRI according to UGT1A1

  • 0 views
  • 23 Jan, 2021
  • 1 location
Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in patients with

metastasis
folfiri regimen
adjuvant chemotherapy
oxaliplatin
neutrophil count
  • 5 views
  • 07 Nov, 2020
  • 1 location
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

compared with bevacizumab (Avastin) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).

metastasis
folfiri regimen
irinotecan
liver metastasis
fluorouracil
  • 1 views
  • 05 Feb, 2021
  • 1 location